210 related articles for article (PubMed ID: 34508743)
1. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
2. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
3. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
4. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
Pelosof L; Yerram S; Armstrong T; Chu N; Danilova L; Yanagisawa B; Hidalgo M; Azad N; Herman JG
Epigenetics; 2017 Jul; 12(7):540-550. PubMed ID: 27918237
[TBL] [Abstract][Full Text] [Related]
5. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
8. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
9. Kinesin family member 18B: A contributor and facilitator in the proliferation and metastasis of cutaneous melanoma.
Yan H; Zhu C; Zhang L
J Biochem Mol Toxicol; 2019 Dec; 33(12):e22409. PubMed ID: 31617652
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
[TBL] [Abstract][Full Text] [Related]
11. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
12. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
[TBL] [Abstract][Full Text] [Related]
13. miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity.
Hua Y; Zhu Y; Zhang J; Zhu Z; Ning Z; Chen H; Liu L; Chen Z; Meng Z
Cell Physiol Biochem; 2018; 51(5):2148-2159. PubMed ID: 30522111
[TBL] [Abstract][Full Text] [Related]
14. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
15. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
[TBL] [Abstract][Full Text] [Related]
16. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
17. PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
Igarashi H; Taniguchi H; Nosho K; Ishigami K; Koide H; Mitsuhashi K; Okita K; Takemasa I; Imai K; Nakase H
Clin Transl Oncol; 2020 Jul; 22(7):1126-1137. PubMed ID: 31741141
[TBL] [Abstract][Full Text] [Related]
18. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Hu W; Lei L; Xie X; Huang L; Cui Q; Dang T; Liu GL; Li Y; Sun X; Zhou Z
Cell Death Dis; 2019 Jul; 10(8):550. PubMed ID: 31320608
[TBL] [Abstract][Full Text] [Related]
20. SIRT1 enhances oxaliplatin resistance in colorectal cancer through microRNA-20b-3p/DEPDC1 axis.
Zhao B; Wang Y; Zhao X; Ni J; Zhu X; Fu Y; Yang F
Cell Biol Int; 2022 Dec; 46(12):2107-2117. PubMed ID: 36200529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
